Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05917145 · ClinicalTrials.gov registry record · Phase 1
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
A Phase 1 study of Glioblastoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT05917145: Recruiting Phase 1 study of Glioblastoma, sponsored by Mayo Clinic.
NCT05917145 is a Phase 1 study of Glioblastoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 94 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05917145, a Phase 1 study of Glioblastoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Primary Outcome
Use Bayesian Optimal Interval (BOIN) design to inform dose escalation and de-escalation decisions and to ultimately determine the maximum tolerated dose level (MTD) of WSD0628 in patient population.
Conditions Studied
Interventions
- DRUG WSD0628
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2024-01-17 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What NCT05917145 shows while recruiting
NCT05917145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which WSD0628 is the first listed.
NCT05917145 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05917145 about?
NCT05917145 is a clinical study titled "ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma". The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
What is the current status of trial NCT05917145?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2024-01-17. Estimated completion is 2029-02.
What conditions does trial NCT05917145 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05917145?
The interventions under investigation include: WSD0628 (DRUG).
Who is sponsoring clinical trial NCT05917145?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05917145 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05917145's enrollment target sits among peer trials
94 49th of 199 higher than 151 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI